In the ZUMA-1 trial, axicabtagene ciloleucel showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma.
from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2T5YnBi
from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2T5YnBi